Download PDF
Thromb Haemost 2002; 87(01): 1-3
DOI: 10.1055/s-0037-1612934
Commentary
Schattauer GmbH

Risk of Recurrent Venous Thomboembolism – Expanding the Frontier

Martin H. Prins
1   Department of Clinical Epidemiology and Medical Technology Assessment, Academic Hospital Maastricht, University of Maastricht, Maastricht, The Netherlands
,
Antonio Marchiori
1   Department of Clinical Epidemiology and Medical Technology Assessment, Academic Hospital Maastricht, University of Maastricht, Maastricht, The Netherlands
2   Department of Medical and Surgical Sciences, Clinica Medica II, University Hospital of Padua, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Norlander S, Leijd B, Jonsson KA, Hjorth M, Linder O, Boberg J. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
    CrossrefPubMedGoogle Scholar
  • 2 Schulman S, Granqvisc S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklung SG, Norlander S, Larfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
    CrossrefPubMedGoogle Scholar
  • 3 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
    CrossrefPubMedGoogle Scholar
  • 4 Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-9.
    CrossrefPubMedGoogle Scholar
  • 5 Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane-Database-Syst-Rev 2000; (03) CD001367.
    PubMedGoogle Scholar
  • 6 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 7 Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med 2000; 160: 769-74.
    CrossrefPubMedGoogle Scholar
  • 8 Lensing AWA, Prins MH. Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis?. Thromb Haemost 1999; 82: 1564-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Prandoni P, Lensing AWA, Prins MH, Simioni P, Bagatella P, Tormene D, Frulla M, Mosena L, Marchiori A, Girolami A. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Thromb Haemost 2001; 86 Suppl. OC 851.
    PubMedGoogle Scholar
  • 11 Piovella F, Crippa L, Barone M, D’Angelo SV, Serafini S, Galli L, Beltrametti C, D’Angelo A. Normalisation rate of compression ultrasonography in symptomatic vs post-surgical acute deep vein thrombosis. Thromb Haemost 2001; 86 Suppl. OC 43.
    PubMedGoogle Scholar
  • 12 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolic recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
    Article in Thieme ConnectPubMedGoogle Scholar